Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical Company has signed an agreement with Wyeth for the product license for Prostap, a luteinizing-hormone releasing hormone agonist, to transfer back to Takeda from Wyeth in the UK and Republic of Ireland.
Subscribe to our email newsletter
This follows the expiry of the agreement between the two companies under which Wyeth has held the marketing authorization for Prostap (leuprorelin acetate) from Takeda in the UK and the Republic of Ireland since 1990.
The marketing for Prostap will now revert to Takeda from July 1, 2009. From this date, the entire Prostap product range will be marketed in the UK and Republic of Ireland by Takeda UK, a wholly owned subsidiary of Takeda.
Wyeth will continue to hold the marketing authorization until this time. Both parties are working closely together to ensure a smooth transition process, in particular recognizing the key importance of maintaining an uninterrupted supply of Prostap products to all patients and customers.
Trevor Smith, managing director of Takeda UK, said: “The addition of Prostap will enrich our product portfolio, which currently consists of Amias, Actos and Competact, and is a logical development of our plan to develop a substantial franchise in the oncology market.”